期刊
VASCULAR PHARMACOLOGY
卷 58, 期 4, 页码 253-258出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.vph.2013.01.003
关键词
Regeneration; Gliptins; DPP-4; Bone marrow
资金
- European Foundation for the Study of Diabetes (EFSD)/Lilly Clinical Investigator Fellowship
Diabetes triggers endothelial dysfunction, which is linked to increased risk of cardiovascular diseases. Stem and progenitor cells from the bone marrow are involved in the maintenance of vascular integrity. Diabetic patients show a dysfunction of these cells, which might represent a novel pathophysiological mechanism of vascular disease. Specifically, stem and progenitor cells fail to egress from the bone marrow (BM) due to BM pathological alterations and unresponsiveness to mobilizing stimuli. In this review, we describe impaired stem cell mobilization in diabetes as a mechanism of failed vascular repair and we provide evidence that pharmacological strategies can restore mobilization. We discuss recent advances in the knowledge of aberrant organization of the diabetic BM and its implications for impaired mobilization. Finally, we describe in detail the pharmacological exploitation of the G-CSF/DPP-4(CD26)/SDF-1 alpha axis as a novel strategy to improve mobilization and attain vascular repair in diabetes. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据